Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore presented to investors at the Pitt Street Research Life Sciences Conference in Sydney last month. Steve speaks to the Anatara story and the exciting year we have ahead with corporate milestones on both our human and animal health product opportunities.
Anatara is currently evaluating a range of evidence-based gastrointestinal consumer health products with a view to expand its current pipeline through in-licencing and distribution. In parallel, the Company continues to remain on-track to announce its human clinical trial protocol and the latest results from the second cohort as part of its current pre-clinical animal studies for its Gastrointestinal ReProgramming dietary supplement, bringing the Company closer to partnering in 2020.
The Company remains focused on building a pipeline of evidence-based human gastrointestinal health products which will provide real outcomes for patients and drive value for its shareholders.